Methylphenidate, rivastigmine or haloperidol in hypoactive delirious intensive care patients: a single centre, randomized, mono-blind pilot trial
Completed
- Conditions
- 10012221ICU-psychosis
- Registration Number
- NL-OMON31220
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 80
Inclusion Criteria
Older than 18 years.
Diagnosed as hypoactive delirium
Exclusion Criteria
Pregnancy; epilepsy; M. Parkinson; Lewy-body dementia; prolonged QT-time; known allergie to the medicinals used; renal replacement therapy; hepatic encephalopathy; hypertheroid; glaucoma; previous suicide attempts; syndrome of Gilles de la Tourette; patients which cannot receive the medication oraly or through a nasogastric tube.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>- the feasibility of a large randomized, placebo controlled, dubbleblind<br /><br>clinical trial to investigate the use of methylfenidate, rivastigmine or<br /><br>haloperidol in hypoactive ICU-delirium.</p><br>
- Secondary Outcome Measures
Name Time Method